Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial

BACKGROUND AND OBJECTIVE: Nearly all patients with multiple myeloma undergo multiple rounds of therapy. The phase III BOSTON trial of once-weekly selinexor and once-weekly bortezomib with dexamethasone (XVd) vs twice-weekly bortezomib and dexamethasone (Vd) is the basis for this cost-effectiveness a...

Descripción completa

Detalles Bibliográficos
Autores principales: Dolph, Michael, Tremblay, Gabriel, Leong, Hoyee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516793/
https://www.ncbi.nlm.nih.gov/pubmed/34368938
http://dx.doi.org/10.1007/s40273-021-01068-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516793/
https://www.ncbi.nlm.nih.gov/pubmed/34368938
http://dx.doi.org/10.1007/s40273-021-01068-9

Ejemplares similares